Free shipping on all orders over $ 500

Sotagliflozin

Cat. No. M5249

All AbMole products are for research use only, cannot be used for human consumption.

Sotagliflozin Structure
Synonym:

LX-4211; LP-802034

Size Price Availability Quantity
2mg USD 48 In stock
5mg USD 80 In stock
10mg USD 120 In stock
25mg USD 235 In stock
50mg USD 350 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Sotagliflozin (LX-4211) is an orally active, first-in-class dual SGLT1/2 inhibitor with IC50s of 36 nM and 1.8 nM, respectively, and is used in studies related to type 1 diabetes and heart failure.

In vitro: Sotagliflozin (LX-4211) inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively.

In vivo: In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Male albino C57BL/6-Tyrc-Brd mice
Formulation Aqueous 0.1% v/v Tween 80
Dosages ~60 mg/kg
Administration p.o.
Chemical Information
Molecular Weight 424.94
Formula C21H25ClO5S
CAS Number 1018899-04-1
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Powell DR, et al. Diabetes Metab Syndr Obes. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.

[2] Powell DR, et al. J Pharmacol Exp Ther. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.

Related SGLT Products
Dapagliflozin

Dapagliflozin (BMS-512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2).

Canagliflozin

Canagliflozin is a potent, selective sodium glucose co-transporter 2 inhibitor.

Empagliflozin

Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.

Phloridzin

Phloridzin is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor.

Phloretin

Phloretin (NSC 407292; RJC 02792) is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2).

  Catalog
Abmole Inhibitor Catalog




Keywords: Sotagliflozin, LX-4211; LP-802034 supplier, SGLT, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.